Genzyme

But Sanofi-Aventis Chief Executive Chris Viehbacher said on Thursday he didn't buy into what he called Genzyme's "rosy" forecasts, saying Sanofi would stay "patient and disciplined", would keep all options open and still preferred to sit down with Genzyme to discuss its value.

Reuters: Top News 2010

Genzyme is considered attractive because it has promising drugs for high cholesterol and other disorders in late development, and it already sells some lucrative drugs for rare genetic disorders.

Sanofi Launches Genzyme Takeover Battle By GREG KELLER 2010

Genzyme is undergoing a four-year plan to fix problems at the manufacturing plant, which failed regulatory inspections and was even temporarily shut down in 2009 due to a viral contamination, causing product shortages.

Sanofi-Aventis to Lay Off 1,700 U.S. Employees Thomas Gryta 2010

Genzyme is holding a meeting Friday with investors and analysts to provide 2011 financial guidance and make its case that the offer doesn't adequately value its existing business, its recovery plans or its pipeline products.

Genzyme Profit Soars as Operating Costs Decline Thomas Gryta 2010

Sanofi also offered a contingent value right, or CVR, that would entitle Genzyme shareholders to additional payments if the company meets certain sales goals.

Sanofi, Genzyme Talks Still On Jeanne Whalen 2011

The drug maker has launched a tender offer to buy all the outstanding shares in Genzyme for $69 each in cash.

Banks, Autos Drop In Europe Parmy Olson 2010

Even if all goes smoothly, Genzyme is unlikely to trade near $69 a share as an independent company in the near term.

Genzyme Plays for Time John Jannarone 2010

Sanofi's tender offer, which was made directly to shareholders of Genzyme, is for $69 per common share.

Now It's Officially Hostile With Sanofi And Genzyme Tom Reese 2010

Sanofi's tender offer, which was made directly to shareholders of Genzyme, is for $69 per common share.

Now It's Officially Hostile With Sanofi And Genzyme Tom Reese 2010

In an interview, Mr. D'Amelio declined to directly comment on any interest in Genzyme Corp., but he implied that Pfizer isn't interested.

Pfizer Profit Declines 70% On Merger, Litigation Costs Thomas Gryta 2010